HCV false positive immunoassays in patients with LVAD: a potential trap!

Over the last decades, left ventricular assist device (LVAD) has become the therapeutic choice for patients with advanced heart failure [1]. Patients benefit from a LVAD in different situations: as a bridge to cardiac transplantation or to recover a better heart function, or as a destination therapy [2]. The outcome of patients with LVAD has improved but it requires a close monitoring to avoid complications as bleeding, stroke, malignant arrhythmias, pump thrombosis and infection.
Source: Journal of Clinical Virology - Category: Virology Authors: Tags: Short Communication Source Type: research